Ute Reuning Selected Research

Vitronectin

11/2014	Cytoplasmic salt bridge formation in integrin αvß3 stabilizes its inactive state affecting integrin-mediated cell biological effects.
7/2011	Integrin αvβ3 promotes vitronectin gene expression in human ovarian cancer cells by implicating rel transcription factors.
6/2011	Vitronectin in vascular context: facets of a multitalented matricellular protein.
8/2009	Integrin alphavbeta3 upregulates integrin-linked kinase expression in human ovarian cancer cells via enhancement of ILK gene transcription.
6/2009	Tumor suppressor KAI1 affects integrin alphavbeta3-mediated ovarian cancer cell adhesion, motility, and proliferation.
1/2008	Integrin alphavbeta3 mediates upregulation of epidermal growth-factor receptor expression and activity in human ovarian cancer cells.
3/2005	ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion.
7/2003	Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ute Reuning Research Topics

Disease

34	Neoplasms (Cancer) 12/2021 - 06/2002
12	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 07/2003
11	Neoplasm Metastasis (Metastasis) 04/2021 - 01/2003
7	Breast Neoplasms (Breast Cancer) 12/2021 - 01/2003
2	Virus Diseases (Viral Diseases) 04/2021 - 01/2019
2	Carcinoma (Carcinomatosis) 02/2004 - 06/2002
1	Fibrosis (Cirrhosis) 04/2021
1	Sepsis (Septicemia) 04/2021
1	Ascites 01/2021
1	Autoimmune Diseases (Autoimmune Disease) 01/2019
1	Triple Negative Breast Neoplasms 01/2017
1	Circulating Neoplastic Cells 10/2012
1	Vascular Diseases (Vascular Disease) 06/2011
1	Thrombosis (Thrombus) 06/2011
1	Atherosclerosis 06/2011
1	Disease Progression 10/2010
1	Vesicular Stomatitis 08/2006
1	Adenoma (Adenomas) 02/2004
1	Colorectal Neoplasms (Colorectal Cancer) 02/2004

Drug/Important Bio-Agent (IBA)

16	IntegrinsIBA 04/2021 - 07/2003
10	Biological ProductsIBA 12/2021 - 01/2006
9	LigandsIBA 04/2021 - 03/2005
8	VitronectinIBA 11/2014 - 07/2003
8	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 06/2011 - 01/2003
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2003
6	Serine Proteases (Serine Protease)IBA 01/2017 - 01/2003
4	Messenger RNA (mRNA)IBA 12/2021 - 07/2003
4	Peptide Hydrolases (Proteases)FDA Link 01/2021 - 01/2003
4	ErbB Receptors (EGF Receptor)IBA 01/2018 - 06/2002
4	Plasminogen Activator Inhibitor 1IBA 11/2010 - 01/2003
4	Integrin alphaVbeta3IBA 08/2009 - 03/2005
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 06/2013
3	TetraspaninsIBA 01/2018 - 06/2009
3	Epidermal Growth Factor (EGF)IBA 01/2018 - 07/2003
2	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 06/2013
2	AntibodiesIBA 09/2017 - 01/2003
2	Pharmaceutical PreparationsIBA 09/2017 - 06/2013
2	Transcription Factors (Transcription Factor)IBA 07/2011 - 07/2003
2	Tumor Biomarkers (Tumor Markers)IBA 11/2010 - 10/2010
2	Plasminogen InactivatorsIBA 11/2010 - 10/2010
2	PlasminogenIBA 10/2010 - 01/2003
2	integrin-linked kinaseIBA 08/2009 - 07/2003
2	Cell Adhesion MoleculesIBA 07/2003 - 06/2002
2	Urokinase Plasminogen Activator ReceptorsIBA 01/2003 - 01/2003
1	Transforming Growth Factors (Transforming Growth Factor)IBA 12/2021
1	GTP-Binding Proteins (G-Protein)IBA 12/2021
1	Chemokine CX3CL1IBA 01/2021
1	Trastuzumab (Herceptin)FDA Link 01/2021
1	arginyl-glycyl-aspartic acidIBA 01/2021
1	ferroceneIBA 01/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021
1	Indicators and Reagents (Reagents)IBA 09/2017
1	PeptidomimeticsIBA 09/2017
1	Tissue Kallikreins (Tissue Kallikrein)IBA 01/2017
1	ParaffinIBA 01/2017
1	kallikrein 4IBA 01/2017
1	Hormones (Hormone)IBA 01/2017
1	SteroidsIBA 01/2017
1	Formaldehyde (Formol)FDA Link 01/2017
1	AnthracyclinesIBA 01/2017
1	Kallikreins (Kallikrein)IBA 01/2017
1	Oncogene Proteins (Oncogene Protein)IBA 01/2017
1	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2016
1	ChemokinesIBA 01/2016
1	Celecoxib (Celebrex)FDA Link 01/2016
1	Indomethacin (Indometacin)FDA LinkGeneric 01/2016
1	Dinoprostone (PGE2)FDA Link 01/2016
1	TalinIBA 11/2014
1	Cytoskeletal ProteinsIBA 11/2014
1	SaltsIBA 11/2014
1	Amino Acids FDA Link 11/2014
1	taxaneIBA 06/2013
1	PlatinumIBA 06/2013
1	Crystallins (Crystallin)IBA 06/2013
1	Epithelial Cell Adhesion MoleculeIBA 10/2012
1	matrigelIBA 06/2011
1	Extracellular Matrix ProteinsIBA 06/2011
1	Glycoproteins (Glycoprotein)IBA 06/2011
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2011
1	Levonorgestrel (Plan B)FDA LinkGeneric 11/2010
1	Tissue ExtractsIBA 11/2010
1	Phosphotransferases (Kinase)IBA 08/2009
1	Rhodopsin (Visual Purple)IBA 08/2006
1	QuartzIBA 01/2005
1	Immobilized ProteinsIBA 01/2005
1	GoldIBA 01/2005
1	Fibronectins (Fibronectin)IBA 08/2004
1	SuspensionsIBA 08/2004
1	beta CateninIBA 02/2004
1	Plasminogen Activators (Plasminogen Activator)IBA 02/2004
1	Integrin alphaVIBA 07/2003
1	Complementary DNA (cDNA)IBA 07/2003
1	3-hydroxyphenyltrimethylammoniumIBA 07/2003
1	prothymosin alphaIBA 07/2003

Therapy/Procedure

9	Therapeutics 04/2021 - 01/2003
2	Orthopedic Procedures 05/2005 - 08/2004
2	Replantation 05/2005 - 08/2004
1	Precision Medicine 09/2017
1	Combination Drug Therapy (Combination Chemotherapy) 01/2017
1	Cannula 10/2012